The antibiotic resistance problems constitute a considerable
threat
to human health worldwide; thus, the discovery of new antimicrobial
candidates to conquer this issue is an imperative requirement. From
this view, new thiophenyl-pyrazolyl-thiazole hybrids 3–10 were synthesized and screened for their antibacterial efficiency
versus Gram – and Gram + bacterial strains compared to the
reference drug amoxicillin. It was noticed that the new hybrids displayed
significant antibacterial efficacy versus Gram – bacteria,
especially against Pseudomonas aeruginosa. Also, all the screened candidates demonstrated a noticeable antifungal
effect against Candida albicans (MICs
= 3.9–125 μg/mL) relative to fluconazole (MIC = 250 μg/mL).
Moreover, the new hybrids were investigated for their antituberculosis
potency against Mycobacterium tuberculosis (RCMB 010126). Derivatives 4c, 6b, 8b, 9b, and 10b demonstrated prominent
antituberculosis efficiency (MICs = 0.12–1.95 μg/mL)
compared with the reference drug isoniazid (MIC = 0.12 μg/mL).
The latter derivatives were further assessed for their inhibitory
potency versus M. tuberculosis DHFR
enzyme. The compounds 4c, 6b and 10b presented a remarkable suppression effect with IC50 values
of 4.21, 5.70, and 10.59 μM, respectively, compared to that
of trimethoprim (IC50 = 6.23 μM). Furthermore, biodistribution
profile using radiolabeling way revealed a perceived uptake of 131I-compound 6b into infection induced models.
The docking study for the new hybrids 4c, 6b, 8b, 9b and 10b was performed
to illustrate the various binding modes with Mtb DHFR
enzyme. In silico ADMET studies for the most potent inhibitors 4c, 6b and 10b were also accomplished
to predict their pharmacokinetic and physicochemical features.